ArticleOpen forum infectious diseases2025
Cefepime Versus Carbapenem Therapy for the Treatment of Invasive Infections With Inducible Chromosomal AmpC-Producing Enterobacterales: A Systematic Review and Meta-analysis.
Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- AmpC β-Lactamase-Producing Microorganisms in South American Hospitals: A Meta-Regression Analysis, Meta-Analysis, and Review of Prevalence.Tropical medicine and infectious disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The optimal antibiotic choice for AmpC-producing Enterobacterales bloodstream infections (BSIs) and complicated urinary tract infections (cUTIs) remains to be clearly defined. Guidance from the Infectious Diseases Society of America recommends cefepime as first-line therapy, based on observational studies. We conducted a systematic review and meta-analysis to compare the clinical outcomes of cefepime versus carbapenems in patients with infections caused by AmpC-producing Enterobacterales. Methods: A systematic search was conducted across Medline, Embase, Cochrane, and Scopus databases to identify studies comparing cefepime and carbapenems for the treatment of BSIs and cUTIs due to AmpC-producing Enterobacterales. Eligible studies reported all-cause mortality as the primary outcome. Secondary outcomes included clinical and microbiological cure, relapse, and adverse events. A random-effects meta-analysis was performed to estimate pooled odds ratios (ORs) with 95% confidence intervals (CIs). Results: Seven studies on BSI encompassing 1099 patients were included, with 479 receiving cefepime and 620 receiving carbapenem as definitive antibiotics. There were no studies on cUTI. No statistically significant difference in all-cause mortality was observed between cefepime and carbapenem treatment (log OR, 0.15 [95% CI, -.33 to .64]; Conclusions: In line with published guidance, treatment outcomes with cefepime did not differ significantly from carbapenems for AmpC-producing BSIs. However, randomized controlled trials are needed to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.